Antibodies that bind to EphA2 and methods of use thereof
Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.
1. A substantially purified immunoglobulin produced by a host cell or progeny thereof with a deposit number of ATCC No. PTA-5070, or an antigen-binding fragment thereof.
2. An isolated antibody that binds to EphA2 comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of antibody LUCA19 produced by the cell line having ATCC No. PTA-5070.
3. The isolated antibody of claim 2 , wherein the isolated antibody is a humanized antibody.
4. The isolated antibody of claim 2 , wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody LUCA19 produced by the cell line having ATCC No. PTA-5070.
5. The isolated antibody of claim 4 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
6. The isolated antibody of claim 2 , wherein the isolated antibody is linked to a therapeutic agent.
7. An antigen-binding fragment of the isolated antibody of claim 2 , wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA19 produced by the cell line having ATCC No. 5070.
8. An isolated antibody that binds to EphA2 comprising a heavy chain variable region from the heavy chain variable region of antibody LUCA19 produced by the cell line having ATCC No. 5070.
9. An isolated antibody that binds to EphA2 comprising a light chain variable region from the light chain variable region of antibody LUCA19 produced by the cell line having ATCC No. 5070.
10. A hybridoma deposited with the American Type Culture Collection having accession number PTA-5070 or progeny thereof.
11. A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable excipient.
12. A pharmaceutical composition comprising the antigen-binding fragment of claim 7 and a pharmaceutically acceptable excipient.
13. A pharmaceutical composition comprising the isolated antibody of claim 8 and a pharmaceutically acceptable excipient.
14. A pharmaceutical composition comprising the isolated antibody of claim 9 and a pharmaceutically acceptable excipient.
15. A substantially purified immunoglobulin produced by a host cell or progeny thereof with a deposit number of ATCC No. PTA-6059, or an antigen-binding fragment thereof.
16. An isolated antibody that binds to EphA2 comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of antibody SPL1 produced by the cell line having ATCC No. PTA-6059.
17. The isolated antibody of claim 16 , wherein the isolated antibody is a humanized antibody.
18. The isolated antibody of claim 16 , wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody SPL1 produced by the cell line having ATCC No. PTA-6059.
19. The isolated antibody of claim 18 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
20. The isolated antibody of claim 16 , wherein the isolated antibody is linked to a therapeutic agent.
21. An antigen-binding fragment of the isolated antibody of claim 16 , wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody SPL1 produced by the cell line having ATCC No. 6059.
22. An isolated antibody that binds to EphA2 comprising a heavy chain variable region from the heavy chain variable region of antibody SPL1 produced by the cell line having ATCC No. 6059.
23. An isolated antibody that binds to EphA2 comprising a light chain variable region from the light chain variable region of antibody SPL1 produced by the cell line having ATCC No. 6059.
24. A hybridoma deposited with the American Type Culture Collection having accession number PTA-6059 or progeny thereof.
25. A pharmaceutical composition comprising the antibody of claim 16 and a pharmaceutically acceptable excipient.
26. A pharmaceutical composition comprising the antigen-binding fragment of claim 21 and a pharmaceutically acceptable excipient.
27. A pharmaceutical composition comprising the isolated antibody of claim 22 and a pharmaceutically acceptable excipient.
28. A pharmaceutical composition comprising the isolated antibody of claim 23 and a pharmaceutically acceptable excipient.
29. A substantially purified immunoglobulin produced by a host cell or progeny thereof with a deposit number of ATCC No. PTA-6056, or an antigen-binding fragment thereof.
30. An isolated antibody that binds to EphA2 comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of antibody LUCA40 produced by the cell line having ATCC No. PTA-6056.
31. The isolated antibody of claim 30 , wherein the isolated antibody is a humanized antibody.
32. The isolated antibody of claim 30 , wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody LUCA40 produced by the cell line having ATCC No. PTA-6056.
33. The isolated antibody of claim 32 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
34. The isolated antibody of claim 30 , wherein the isolated antibody is linked to a therapeutic agent.
35. An antigen-binding fragment of the isolated antibody of claim 30 , wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA40 produced by the cell line having ATCC No. 6056.
36. An isolated antibody that binds to EphA2 comprising a heavy chain variable region from the heavy chain variable region of antibody LUCA40 produced by the cell line having ATCC No. 6056.
37. An isolated antibody that binds to EphA2 comprising a light chain variable region from the light chain variable region of antibody LUCA40 produced by the cell line having ATCC No. 6056.
38. A hybridoma deposited with the American Type Culture Collection having accession number PTA-6056 or progeny thereof.
39. A pharmaceutical composition comprising the antibody of claim 30 and a pharmaceutically acceptable excipient.
40. A pharmaceutical composition comprising the antigen-binding fragment of claim 35 and a pharmaceutically acceptable excipient.
41. A pharmaceutical composition comprising the isolated antibody of claim 36 and a pharmaceutically acceptable excipient.
42. A pharmaceutical composition comprising the isolated antibody of claim 37 and a pharmaceutically acceptable excipient.
43. A substantially purified immunoglobulin produced by a host cell or progeny thereof with a deposit number of ATCC No. PTA-7356, or an antigen-binding fragment thereof.
44. An isolated antibody that binds to EphA2 comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of antibody SG5 produced by the cell line having ATCC No. PTA-7356.
45. The isolated antibody of claim 44 , wherein the isolated antibody is a humanized antibody.
46. The isolated antibody of claim 44 , wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody SG5 produced by the cell line having ATCC No. PTA-7356.
47. The isolated antibody of claim 46 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
48. The isolated antibody of claim 44 , wherein the isolated antibody is linked to a therapeutic agent.
49. An antigen-binding fragment of the isolated antibody of claim 44 , wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody SG5 produced by the cell line having ATCC No. 7356.
50. An isolated antibody that binds to EphA2 comprising a heavy chain variable region from the heavy chain variable region of antibody SG5 produced by the cell line having ATCC No. 7356.
51. An isolated antibody that binds to EphA2 comprising a light chain variable region from the light chain variable region of antibody SG5 produced by the cell line having ATCC No. 7356.
52. A hybridoma deposited with the American Type Culture Collection having accession number PTA-7356 or progeny thereof.
53. A pharmaceutical composition comprising the antibody of claim 44 and a pharmaceutically acceptable excipient.
54. A pharmaceutical composition comprising the antigen-binding fragment of claim 49 and a pharmaceutically acceptable excipient.
55. A pharmaceutical composition comprising the isolated antibody of claim 50 and a pharmaceutically acceptable excipient.
56. A pharmaceutical composition comprising the isolated antibody of claim 51 and a pharmaceutically acceptable excipient.